Skip to main content

NEUROCRINE BIOSCIENCES INC

For the period ended Jun 30, 2025. Filed Jul 30, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Jul 30, 2025

NBIX$168.86+2.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

(in millions, except per share data)June 30,2025December 31,2024
Assets
Current assets:
Cash and cash equivalents$264.0$233.0
Available-for-sale debt securities711.6843.1
Accounts receivable595.7479.1
Inventory56.957.4
Other current assets120.7112.1
Total current assets1,748.91,724.7
Deferred tax assets536.8485.7
Available-for-sale debt securities873.8739.5
Right-of-use assets492.3509.4
Equity investments87.5124.8
Property and equipment, net91.782.6
Intangible assets, net37.236.5
Other noncurrent assets21.615.5
Total assets$3,889.8$3,718.7
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued liabilities$489.5$461.6
Other current liabilities56.846.1
Total current liabilities546.3507.7
Noncurrent operating lease liabilities439.1455.1
Other noncurrent liabilities210.1166.2
Total liabilities1,195.51,129.0
Stockholders’ equity:
Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding——
Common stock, $0.001 par value; 220.0 shares authorized; 99.0 and 99.4 shares issued and outstanding, respectively0.10.1
Additional paid-in capital2,597.22,554.6
Accumulated other comprehensive income12.55.8
Retained earnings84.529.2
Total stockholders’ equity2,694.32,589.7
Total liabilities and stockholders’ equity$3,889.8$3,718.7
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.